MedTrace Logo

Bifido- and Lactobacilli in Symptomatic Adult COVID-19 Outpatients

NCT04907877 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2023-03-22

No results posted yet for this study

Summary

There is evidence that some types of probiotics play a role in alleviation of symptoms of acute respiratory tract infections and bursting immune response to respiratory and enteric viruses. Available data serves a rationale for the study exploring a role of nutritional support with probiotics in adult outpatients with COVID-19. Hypothesis of the study is that a proposed mixture of lactobacilli and bifidobacteria facilitate faster recovery from COVID-19 and enhance specific immune response to SARS-CoV-2 antigens.

Conditions

  • COVID-19 Respiratory Infection

Interventions

DIETARY_SUPPLEMENT

Probiotic

Probiotic will be taken 1 time a day before breakfast for 28 days.

DIETARY_SUPPLEMENT

Placebo

Placebo will be taken 1 time a day before breakfast for 28 days.

Sponsors & Collaborators

  • Nordic Biotic Sp. z o.o.

    lead INDUSTRY

Principal Investigators

  • Zoriana Hoda, MD · Lviv State Laboratory Center, Ministry of Health of Ukraine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-01
Primary Completion
2022-12-01
Completion
2023-03-01

Countries

  • Ukraine

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04907877 on ClinicalTrials.gov